Candidiasis, Vulvovaginal Clinical Trial
Official title:
Studie Van de Vaginale Microbiota en Het Potentieel Van Een Vaginale Zalf Met Probiotica Bij Vaginale Candidose
Verified date | June 2019 |
Source | University Hospital, Antwerp |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluated the effect of a vaginal gel containing three live probiotic bacteria on vaginal Candida albicans infection in flemish patients (n=20). The therapeutic effects of the gel will be clinically evaluated (vaginal pH, microscopic and clinical scores). The effect on the vaginal microbiome will be evaluated through 16S ribosomal RNA amplicon sequencing via MiSeq Illumina and polymerase chain reaction (PCR) for Candida albicans.
Status | Completed |
Enrollment | 20 |
Est. completion date | March 31, 2017 |
Est. primary completion date | March 31, 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Informed consent - willing to adhere to protocol - premenopausal - positive Candida microscopy and/or culture - at least two of the following vaginal symptoms: burning, itching, redness, fissure, discharge, vulvar edema, postcoital itching, lesions with partner Exclusion Criteria: - vaginal use of any products 1 week or less before randomization - use of oral or local antimycotic treatment 1 week or less before randomization - unprotected sexual contact 24 hours preceding randomization - vaginal douching 24 hours preceding randomization - patient does not agree to participate in the study |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Antwerp |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Vaginal persistence of Candida species | The presence of Candida species in the collected samples will be analyzed by microscopy, culture (clinical lab) and after DNA extraction through quantitative PCR as molecular method. This will allow to estimate relative and absolute concentrations of the suspected infectious agent, and allow to evaluate if the infection cleared or not. | through study completion, estimated 1 year | |
Secondary | Clinical scores of patients | By the responsible gynecologist, symptom severity (burning, itching, redness, swelling and fissures) was estimated and scored as absent, mild, moderate or severe. This will provide information about the ability of the gel to ameliorate the symptoms of vulvovaginal candidosis. | through study completion, estimated 1 year | |
Secondary | Microbiome analysis | After Illumina MiSeq sequencing, bio-informatics tools will be used to cluster bacteria and yeasts into operation taxonomic units/ amplicon sequence variants (ASVs). Based on these ASVs, the bacterial and fungal community will be compared over the sampled periods and allow comparison of the composition over the study period. The investigators will specifically screen for ASVs that can be expected to be derived from supplied probiotic strains or that are responsible for the infection (expected Candida ASVs). Additionally, the investigators will pay attention to the dominant members of the vaginal bacterial community (expected in most women to be dominated by one of four Lactobacillus species). | through study completion, estimated 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02971007 -
Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)
|
Phase 2 | |
Completed |
NCT02251093 -
Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis
|
Phase 3 | |
Completed |
NCT01293643 -
A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077)
|
Phase 3 | |
Not yet recruiting |
NCT04626258 -
Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis
|
Phase 4 | |
Completed |
NCT02733432 -
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
|
Phase 2 | |
Completed |
NCT02248506 -
Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis
|
Phase 4 | |
Completed |
NCT02730494 -
Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation
|
Phase 1 | |
Completed |
NCT02180828 -
Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis
|
Phase 4 | |
Recruiting |
NCT04930107 -
Vulvovaginal Candidiasis in Canadian Females
|
Early Phase 1 | |
Withdrawn |
NCT03167957 -
Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis
|
Phase 2 | |
Recruiting |
NCT05367089 -
The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms
|
Phase 3 | |
Terminated |
NCT02859493 -
Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis
|
N/A | |
Completed |
NCT01891331 -
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
|
Phase 2 | |
Completed |
NCT02888197 -
Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization
|
N/A | |
Recruiting |
NCT05059145 -
A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis
|
Phase 2 | |
Recruiting |
NCT03075046 -
Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial
|
N/A |